Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib +/- Lenalidomide in Refractory Thyroid Cancer
NCT01208051Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2010
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of cediranib in differentiated thyroid cancer (DTC) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Dose Limiting Toxicity at 28 days and Progression-free Survival at 3 years. Started Sep 2010; status: completed.
02
Drugs
cediranib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT01208051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01208051.